BMS, Repertoire Ink Potential $1.8B Looking for Autoimmune Disease Vaccine Deals


Bristol-Myers Squibb/iStock, JHVEPhoto

Pictured: BMS signature on a building in San Diego, California/iStock, JHVEPhoto

Bristol Myers Squibb announced on Monday that it has entered into a multi-year collaboration with Repertoire Immune Medicines that could be worth $1.8 billion to develop tolerable vaccines against up to three autoimmune diseases.

Under the agreement, BMS will pay Repertoire $65 million upfront, and the biotech is eligible to receive additional milestone payments and potential tiered royalties. Repertoire will be responsible for leading all activities for the vaccine up to the development nomination stage. BMS will then take over clinical development, regulatory affairs and commercialization under the global license.

According to Repertoire, the deal will use its Decode discovery platform to find vaccine candidates. Decode is a T cell receptor epitope platform using proprietary lipid nanoparticle delivery technology. The biotech company said the vaccine aims to treat the underlying cause by “resetting” the immune system. However, no details were provided on which specific diseases were targeted.

“Our collaboration with Repertoire aims to selectively reset the immune system, reflecting a key component of our immunology research strategy, which we believe may provide long-term benefits while mitigating the unintended consequences associated with widespread immunosuppression,” ” said Francisco Ramírez-Valle, head of the company. The BMS Center for Topic Research in Immunology and Cardiovascular said in a statement.

Repertoire was founded by Flagship Pioneering in 2019 and launched in 2020, but faced difficulties in 2022. The tumors came back positive after phase I trial data showed it had limited effectiveness. Repertoire focuses on using the Decode platform to find targets in cancer, autoimmune diseases and infectious diseases.

“This agreement is a recognition of the transformative ability of the Repertoire Decode platform to discover and develop programmable T cell-targeted immunotherapeutics,” Repertoire CEO Torben Straight Nissen said in a statement. “We are pleased to partner with Bristol-Myers Squibb. , combining their leadership in immunology with our unique ability to discover key disease-associated epitopes in patients with autoimmune diseases.”

BMS has been active in the trading space recently. Last week, the company signed a $380 million booking and supply agreement with manufacturer Cellares to ramp up production of CAR-T cell therapies.

The pharmaceutical company also announced in its first-quarter 2024 earnings report that it plans to save $1.5 billion in costs in 2025, including cutting 2,200 jobs by the end of the year.

Tyler Patchen is biospace. You can contact him at tyler.patchen@biospace.com. Follow him on LinkedIn.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top